Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 5:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 72 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: HFrEF Clear all
Completed Phase 2 Interventional

Evaluate Efficacy, Safety and Tolerability of JTT-861 in Subjects With Heart Failure With Reduced Ejection Fraction

NCT06017609
View directory record Official record
Conditions
Chronic Heart Failure
Interventions
JTT-861 Capsules, Placebo Capsules
Drug
Lead sponsor
Akros Pharma Inc.
Industry
Eligibility
30 Years to 85 Years
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
20
States / cities
Phoenix, Arizona • Crystal River, Florida • Hialeah, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 17, 2026, 5:15 AM EDT
Recruiting Not applicable Interventional

PRIME HFrEF: Novel Exercise for Older Patients With Heart Failure With Reduced Ejection Fraction

NCT05609097
View directory record Official record
Conditions
Heart Failure With Reduced Ejection Fraction
Interventions
PRIME, COMBO
Other
Lead sponsor
University of Virginia
Other
Eligibility
65 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 6, 2025 · Synced Oct 17, 2026, 5:15 AM EDT
Enrolling by invitation Phase 4 Interventional

Pilot Study of StudyU for N-of-1 Trials in HFrEF Patients (N-of-1 App)

NCT07252310
View directory record Official record
Conditions
HFrEF - Heart Failure With Reduced Ejection Fraction, Heart Failure, Heart Failure, Systolic, Heart Diseases
Interventions
beta blockers, StudyU Application
Drug · Device
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
65 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 17, 2026, 5:15 AM EDT
Terminated Phase 2 Interventional Results available

Effectiveness of CRD-740 in Heart Failure

NCT05409183
View directory record Official record
Conditions
Heart Failure, Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction, Cardiovascular Diseases, Heart Diseases
Interventions
CRD-740, Placebo
Drug
Lead sponsor
Cardurion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
17
States / cities
Alexander City, Alabama • Birmingham, Alabama • Fairhope, Alabama + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2024 · Synced Oct 17, 2026, 5:15 AM EDT
Completed Phase 2 Interventional Results available

A Study to Learn How Safe Starting Vericiguat at a Dose of 5 Milligrams is in Participants With Chronic Heart Failure With Reduced Ejection Fraction

NCT06195930
View directory record Official record
Conditions
Chronic Heart Failure With Reduced Ejection Fraction
Interventions
Vericiguat (BAY1021189) 5 mg
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
5
States / cities
Alexander City, Alabama • Richmond, Indiana • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Oct 17, 2026, 5:15 AM EDT
Completed Early Phase 1 Interventional

Exercise and NO in HFrEF

NCT03136029
View directory record Official record
Conditions
Heart Failure With Reduced Ejection Fraction
Interventions
Antioxidant, Tetrahydrobiopterin (BH4), Exercise training
Dietary Supplement · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Oct 17, 2026, 5:15 AM EDT
Completed Phase 4 Interventional Results available

Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes.

NCT02887183
View directory record Official record
Conditions
Heart Failure
Interventions
LCZ696 (sacubitril/valsartan)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
794 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
77
States / cities
Birmingham, Alabama • Fort Payne, Alabama • Guntersville, Alabama + 66 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2021 · Synced Oct 17, 2026, 5:15 AM EDT
Completed Phase 1 Interventional

A Study to Assess the Effect of Danicamtiv on the Drug Levels of Midazolam in Participants With Stable Heart Failure

NCT05952089
View directory record Official record
Conditions
Heart Failure With Reduced Ejection Fraction
Interventions
Danicamtiv, Midazolam
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
5
States / cities
Fort Lauderdale, Florida • Inverness, Florida • Jacksonville, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2024 · Synced Oct 17, 2026, 5:15 AM EDT
Recruiting Not applicable Interventional

PRagmatic Trial Of Messaging to Providers About Treatment of Heart Failure at Inova

NCT05433220
View directory record Official record
Conditions
Heart Failure
Interventions
Best Practice Advisory using Electronic Health Record
Other
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 17, 2026, 5:15 AM EDT
Not yet recruiting Not applicable Interventional

Boston Medical Center Ultrasound Decongestion Study in Heart Failure

NCT07096726
View directory record Official record
Conditions
Congestive Heart Failure, Volume Overload
Interventions
Five-point ultrasound, Standard of care
Device · Other
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 17, 2026, 5:15 AM EDT
Completed No phase listed Observational

Role of Sacubitril/Valsartan in Improving Provider Performance in Managing Heart Failure Under Medicare Alternative Payment Models

NCT05096039
View directory record Official record
Conditions
Heart Failure
Interventions
Sacubitril/valsartan, ACEI or ARB and no sacubitril/valsartan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
1,614,719 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 16, 2021 · Synced Oct 17, 2026, 5:15 AM EDT
Recruiting Early Phase 1 Interventional

Ketones, SGLT2, HFrEF

NCT06229678
View directory record Official record
Conditions
Type2diabetes, Heart Failure With Reduced Ejection Fraction
Interventions
Empagliflozin 25 MG Oral Tablet, Placebo, Acipimox 250 Mg Oral Capsule
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 70 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 17, 2026, 5:15 AM EDT
Completed Phase 4 Interventional

ERTU-SODIUM: Study on the Effects of Ertugliflozin on Sodium Storage, Interstitial Volume, and Plasma Volume in HFrEF

NCT05152940
View directory record Official record
Conditions
Heart Failure With Reduced Ejection Fraction, Congestion
Interventions
Ertugliflozin, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 17, 2026, 5:15 AM EDT
Recruiting Not applicable Interventional

Impact of Barostimulation on Hemodynamics in Adults With Heart Failure

NCT07335510
View directory record Official record
Conditions
HFrEF - Heart Failure With Reduced Ejection Fraction
Interventions
Baroreflex Activation Therapy
Device
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
7
States / cities
San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 17, 2026, 5:15 AM EDT
Recruiting Phase 4 Interventional

Colchicine in Acutely Decompensated HFREF

NCT06286423
View directory record Official record
Conditions
Heart Failure, Decompensated Heart Failure, Heart Failure With Reduced Ejection Fraction
Interventions
Colchicine 0.6 mg, Control/Placebo group
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 8, 2024 · Synced Oct 17, 2026, 5:15 AM EDT
Not listed Not applicable Interventional

BAROSTIM® Hope for Heart Failure Study

NCT01720160
View directory record Official record
Conditions
Heart Failure
Interventions
BAROSTIM NEO® System, Standard of care medical managment therapy for heart failure
Device · Other
Lead sponsor
CVRx, Inc.
Industry
Eligibility
21 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
23
States / cities
Mesa, Arizona • Phoenix, Arizona • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated May 14, 2019 · Synced Oct 17, 2026, 5:15 AM EDT
Active, not recruiting Not applicable Interventional

REDUCE LAP-HFREF TRIAL

NCT03093961
View directory record Official record
Conditions
Heart Failure
Interventions
IASD implant
Device
Lead sponsor
Corvia Medical
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 6, 2024 · Synced Oct 17, 2026, 5:15 AM EDT
Recruiting Phase 2 Interventional

A Trial of CRD-4730 in HFrEF

NCT07750873
View directory record Official record
Conditions
Heart Failure With Reduced Ejection Fraction (HFrEF)
Interventions
CRD-4730, Placebo
Drug
Lead sponsor
Cardurion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
525 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Pasadena, California • Bloomfield Hills, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 17, 2026, 5:15 AM EDT
Completed Phase 2 Interventional

A Study to Assess Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Reduced Ejection Fraction (Cycle-1-REF)

NCT06215911
View directory record Official record
Conditions
Heart Failure, Heart Failure With Reduced Ejection Fraction, Cardiovascular Diseases, Heart Diseases
Interventions
Tovinontrine (CRD-750), Placebo
Drug
Lead sponsor
Cardurion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
557 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
26
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Beverly Hills, California + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 17, 2026, 5:15 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Assess the Hemodynamic Effects, Safety, Tolerability, and Pharmacokinetics of Intravenous APD418 in Adult Participants With Heart Failure With Reduced Ejection Fraction

NCT05139615
View directory record Official record
Conditions
Acute Heart Failure With Reduced Ejection Fraction
Interventions
APD418, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 85 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
5
States / cities
Tampa, Florida • Peoria, Illinois • Houston, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2023 · Synced Oct 17, 2026, 5:15 AM EDT
Completed Phase 3 Interventional Results available

DETERMINE-reduced - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Reduced Ejection Fraction

NCT03877237
View directory record Official record
Conditions
Heart Failure With Reduced Ejection Fraction (HFrEF)
Interventions
Dapagliflozin, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 150 Years
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
23
States / cities
Alexander City, Alabama • Fairhope, Alabama • Fort Payne, Alabama + 19 more
Source: ClinicalTrials.gov public record
Updated May 5, 2021 · Synced Oct 17, 2026, 5:15 AM EDT
Completed Phase 3 Interventional Results available

This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms

NCT03448419
View directory record Official record
Conditions
Heart Failure
Interventions
Empagliflozin, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
41
States / cities
Mobile, Alabama • Saraland, Alabama • Huntington Beach, California + 37 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2020 · Synced Oct 17, 2026, 5:15 AM EDT
Completed Phase 4 Interventional Results available

Study of Effects of Sacubitril/Valsartan vs. Enalapril on Aortic Stiffness in Patients With Mild to Moderate HF With Reduced Ejection Fraction

NCT02874794
View directory record Official record
Conditions
Heart Failure and Reduced Ejection Fraction
Interventions
LCZ696 (sacubitril/valsartan), Enalapril, Placebo of Enalapril, Placebo of LCZ696
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
81
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Beverly Hills, California + 69 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 17, 2026, 5:15 AM EDT
Completed Phase 4 Interventional Results available

The Effect of Vericiguat on Peripheral Vascular Function, Patient Health Status and Inflammation

NCT05420012
View directory record Official record
Conditions
Heart Failure, Heart Failure With Reduced Ejection Fraction (HFrEF)
Interventions
Vericiguat, Placebo
Drug
Lead sponsor
Josef Stehlik
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced Oct 17, 2026, 5:15 AM EDT